Goldman Sachs Initiates Coverage On Tarsus Pharmaceuticals with Neutral Rating, Announces Price Target of $19
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Andrea Tan has initiated coverage on Tarsus Pharmaceuticals (NASDAQ:TARS) with a Neutral rating and set a price target of $19.

November 20, 2023 | 9:43 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Goldman Sachs has initiated coverage on Tarsus Pharmaceuticals with a Neutral rating and a price target of $19.
The initiation of coverage by Goldman Sachs with a Neutral rating suggests a balanced view on Tarsus Pharmaceuticals' stock without a strong bullish or bearish bias. The price target of $19 provides a reference point for investors but does not imply significant upside or downside, hence the neutral score. The relevance is high as the news directly pertains to TARS. The importance is significant as analyst ratings can influence investor perception and stock price, but it is not at the highest level as the rating is neutral rather than a buy or sell. The confidence level is high due to the credibility of Goldman Sachs as a financial institution, although not at the maximum since market conditions can change rapidly.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100